Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28332769 | 0.98 | KDM1A (0.44) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL18787264 | 0.95 | KDM1A (0.48) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL29703994 | 0.95 | KDM1A (0.48) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL28182366 | 0.83 | KDM1A (0.46) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL13753876 | 0.80 | MEN1 (0.56) | MAPK1MAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL3168485 | 0.80 | CYP4F2 (0.51) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL9454115 | 0.80 | MRGPRX4 (0.46) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL11688841 | 0.79 | MEN1 (0.55) | MAPK1MAPTTDP1L3MBTL1MEN1 | |
| SCHEMBL31473328 | 0.78 | KDM1A (0.44) | KDM1AMAPK1MAPTTDP1L3MBTL1 | |
| SCHEMBL17367259 | 0.78 | MAPT (0.53) | KDM1AMAPK1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786517-B2 | Methods of treatment using a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3619208-B1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220306624-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220008403-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-11160800-B2 | Methods of treatment using a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| CN-108349972-B | JAK kinase inhibitor compounds for the treatment of respiratory diseases | 施万生物制药研发IP有限责任公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20210130351-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10913740-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-10251874-B2 | Crystalline forms of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| US-10183942-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180319796-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2018204236-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180311223-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20180311226-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-01 | — | — | US | disclosed |
| US-10100049-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3371186-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | Theravance Biopharma R&D IP, LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079205-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913740-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-11299492-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-11786517-B2 | Methods of treatment using a JAK inhibitor compound | JAK1, JAK2, JAK3 | KDM1A 355/4885MAPK1 146/4885MAPT 3933/4885 |
| US-20180311223-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | KDM1A 353/4885MAPK1 278/4885MAPT 1817/4885 |
| US-20220306624-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-20210130351-A1 | JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-20220008403-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | KDM1A 355/4885MAPK1 146/4885MAPT 3933/4885 |
| US-20180319796-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-20170121327-A1 | JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-11160800-B2 | Methods of treatment using a JAK inhibitor compound | JAK1, JAK2, JAK3 | KDM1A 355/4885MAPK1 146/4885MAPT 3933/4885 |
| US-10183942-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
| US-20180311226-A1 | METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | KDM1A 355/4885MAPK1 146/4885MAPT 3933/4885 |
| US-10251874-B2 | Crystalline forms of a JAK inhibitor compound | JAK1, JAK2, JAK3 | KDM1A 353/4885MAPK1 278/4885MAPT 1817/4885 |
| US-10100049-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | KDM1A 473/4885MAPK1 57/4885MAPT 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.